HERZLIYA, ISRAEL — February 4, 2026 — Leads & Copy — Regentis Biomaterials Ltd. (NYSE American:RGNT), a regenerative medicine company focused on tissue repair solutions, has appointed Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately.
Gon will lead the company’s commercial and business development activities, as well as its financial strategy, planning, and reporting.
Gon joins Regentis as GelrinC, the company’s hydrogel implant for knee cartilage repair, advances toward commercial launch in Europe following CE Mark approval. It is also being evaluated in a Phase III FDA clinical trial in the United States.
GelrinC is the only restorative product for knee cartilage repair and is at the midpoint of a pivotal FDA Phase III trial in the U.S.
Dr. Ehud Geller, Executive Chairman of Regentis, said Gon’s appointment strengthens the leadership team as the company transitions from development to commercialization. He added that Gon’s experience as a public company CFO, combined with his business development expertise, will be instrumental as the company evaluates partnerships to launch GelrinC in Europe and build the foundation for growth.
Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. He most recently served as CFO at Tactile Mobility, a sensing and data analytics company focused on automotive and mobility applications. He also held senior financial leadership roles at ReWalk Robotics, Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons, where he served as CFO and Corporate Controller.
Earlier in his career, Gon was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his career as an auditor at KPMG Israel.
Gon has led multiple secondary public offerings and financing transactions, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.
Gon said he is excited to join Regentis at such an important time. He added that with GelrinC approaching commercialization in Europe and progressing through a pivotal FDA trial in the U.S., Regentis is uniquely positioned to transform the treatment landscape for knee cartilage repair.
GelrinC is a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to focal articular knee cartilage. It offers surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date.
Regentis Biomaterials Ltd is a regenerative medicine company developing tissue repair solutions. Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.
Source: Regentis Biomaterials Ltd
